PCI Synthesis is a Pharmaceutical Development CDMO (Contract Development and Manufacturing Organization) based in Newburyport, Mass. and is the largest small molecule drug substance manufacturer in New England. A wholly-owned subsidiary of Novacap, PCI Synthesis is also a commercial manufacturer of new chemical entities (NCEs), generic active pharmaceutical ingredients (APIs), and other specialty chemical products for the medical device industry. As a CDMO, PCI Synthesis provides emerging and mid-sized pharmaceutical companies access to the expertise needed to develop and manufacture complex small molecules. PCI Synthesis offers cGMP solutions to develop a final API, including process research, process development, analytical development, process validation, regulatory support & FDA filing. PCI Synthesis operates two FDA inspected sites in the Boston area. Please visit www.pcisynthesis.com.
Founded in 1987, Dec is a leading global provider of powder handling systems to the pharmaceutical, chemical, food and cosmetic industries. Its turnkey and custom-designed solutions have been successfully integrated into complex operations in a large number of companies worldwide, both... Read More
Admix provides solutions to tough pharmaceutical mixing challenges. Our sanitary, stainless steel high shear batch mixers, dispersers, emulsifiers, wet mills, static mixers, low-speed large capacity agitators, and powder dispersion and induction systems are all designed to meet stringent...
Through exclusive development and partnerships with API manufacturers, ChemWerth provides expertise in product selection & development; analytical and regulatory services and strong project management to ensure the highest standards of quality
PCI Synthesis offers a wide range of chemical products including: Aromatics, Imidazoles/Imidazolines, Indoles, Oxazoles, Phosphonic acids, photo imaging, Purines, Pyridines, Pyrimidines and Tetralones. They are immediately available for shipment. Read more